ARS Pharmaceuticals, Inc.(SPRY)

Biotechnology · San Diego, CA

$4.30+0.00 (+0.12%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T22:30:46.448Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:30:46.448Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -212,685,000
Quote market capitalization: 426,507,510
Total debt · period ending 2026-06-30: 171,603,000
Cash · period ending 2026-06-30: 8,163,000

FMP input reference: 245dd754b0f03b0474a1f4d6c5429d137941524b53a54e0755d3e87780725df6

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SPRY EBITDA Yield Metrics

EBITDA YIELD

N/A

SPRY Competitors' EBITDA Yield

SPRY

ARS Pharmaceuticals, Inc.

Current

Market Cap

$426.51M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEO

NeoGenomics, Inc.

vs SPRY

Market Cap

$424.10M

EBITDA Yield

N/A

TTM Avg

1.44%

3Y Avg

5.28%

5Y Avg

7.05%

TECX

Tectonic Therapeutic, Inc.

vs SPRY

Market Cap

$422.86M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLRY

Tilray Brands, Inc.

vs SPRY

Market Cap

$422.72M

EBITDA Yield

4.37%

TTM Avg

3.97%

3Y Avg

3.97%

5Y Avg

3.97%

NPCE

NeuroPace, Inc.

vs SPRY

Market Cap

$431.97M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRTA

Prothena Corporation plc

vs SPRY

Market Cap

$419.87M

EBITDA Yield

N/A

TTM Avg

6.82%

3Y Avg

6.82%

5Y Avg

6.82%

EDIT

Editas Medicine, Inc.

vs SPRY

Market Cap

$418.95M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

YDES

YD Bio Limited Ordinary Shares

vs SPRY

Market Cap

$435.61M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SENS

Senseonics Holdings, Inc.

vs SPRY

Market Cap

$416.27M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RZLT

Rezolute, Inc.

vs SPRY

Market Cap

$415.98M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
ARS Pharmaceuticals, Inc. (SPRY)	$426.51M	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$424.10M	N/A	1.44%	5.28%	7.05%
Tectonic Therapeutic, Inc. (TECX)vs ›	$422.86M	N/A	N/A	N/A	N/A
Tilray Brands, Inc. (TLRY)vs ›	$422.72M	4.37%	3.97%	3.97%	3.97%
NeuroPace, Inc. (NPCE)vs ›	$431.97M	N/A	N/A	N/A	N/A
Prothena Corporation plc (PRTA)vs ›	$419.87M	N/A	6.82%	6.82%	6.82%
Editas Medicine, Inc. (EDIT)vs ›	$418.95M	N/A	N/A	N/A	N/A
YD Bio Limited Ordinary Shares (YDES)vs ›	$435.61M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$416.27M	N/A	N/A	N/A	N/A
Rezolute, Inc. (RZLT)vs ›	$415.98M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

SPRY EBITDA Yield Metrics

SPRY Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics